Business Context and Reporting Period
Company: Alterity Therapeutics Limited (ASX: ALR)
Filing Type: Form 6-K (Appendix 4C Quarterly Report)
Reporting Period: Quarter ended March 31, 2019 (Current Quarter) and Year-to-Date (9 months).
Business Overview: The registrant is a biotechnology company focused on research and development. The filing details cash flow activities, financing, and operational expenditures for the quarter.
Key Financial Metrics
| Metric | Current Quarter ($A'000) | Year-to-Date ($A'000) |
|---|---|---|
| Cash and Cash Equivalents (End of Period) | 8,910 | 8,910 |
| Net Cash from Operating Activities | (839) | (8,086) |
| Net Cash from Financing Activities | 1,411 | 1,570 |
| Net Increase in Cash | 8,383 | 15,236 |
| Government Grants Received | 3,252 | 3,252 |
| Staff Costs Paid | (950) | (2,812) |
| Research & Development Costs Paid | (2,523) | (7,000) |
Note: The filing provides a cash flow statement only. Revenue, profit, margins, and debt balances are not explicitly stated in the provided text.
Material Changes and Financing Activities
- Share Issuance: The company raised A$1,478,000 from the issue of shares in the current quarter, with A$67,000 in associated transaction costs.
- Government Support: Significant cash inflow of A$3,252,000 was received from government grants and tax incentives during the quarter.
- Operating Burn: Net cash used in operating activities was A$839,000 for the quarter, driven primarily by R&D and staff costs.
- Subsequent Event: Following shareholder approval on April 8, 2019, the company completed a strategic investment by Life Biosciences LLC totaling A$10.526 million, plus a placement of A$913,807 to other investors.
Outlook, Risks, and Management Commentary
- Estimated Cash Outflows (Next Quarter): Management estimates total cash outflows of A$6,540,000 for the upcoming quarter.
- Research and Development: A$4,000,000
- Administration and Corporate Costs: A$1,500,000
- Staff Costs: A$1,000,000
- Advertising and Marketing: A$40,000
- Liquidity Position: As of March 31, 2019, cash and cash equivalents stood at A$8,910,000. This includes A$4,910,000 in bank balances and A$4,000,000 in call deposits.
- Debt Facilities: The company reported no loan facilities or credit standby arrangements drawn or available at quarter end.
Investor Verification Checklist
- Capital Raise Impact: Verify the final closing details and share count impact of the A$11.4+ million strategic investment by Life Biosciences LLC announced post-quarter.
- Runway Analysis: Compare the A$8.91 million cash balance against the estimated A$6.54 million quarterly burn rate to assess immediate liquidity runway.
- Grant Sustainability: Confirm the nature and duration of the A$3.25 million government grants to determine if this is a recurring revenue stream or a one-time event.
- R&D Milestones: Review the specific R&D projects consuming A$2.5 million in the quarter to assess progress against the A$4 million projected spend for the next quarter.